EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Treatment adjustment in biologic therapies for moderate‐to‐severe plaque psoriasis: a German retrospective chart review (TABU)

Natalia Kirsten, Simone Rubant, Susana Gomis-Kleindienst, Heike Pfeiffer-Vornkahl, Matthias Augustin iD

JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2024

DOI: 10.1111/ddg.15448 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2024. Verfasst von Natalia Kirsten und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany. Hauptthemen laut MEDLINE: Psoriasis. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives Flexible biologic therapy dosing regimens in psoriasis management are common, but data from routine care in Germany are scarce. This study evaluated treatment adjustments for biologic therapies commonly prescribed in Germany. Patients and methods Charts for up to 100 consecutive patients treated at 29 centers were reviewed. Data were extracted for adults (aged 18–65 years) with moderate‐to‐severe plaque psoriasis treated with adalimumab, guselkumab, ixekizumab, secukinumab, or ustekinumab for ≥ 36 weeks. The primary endpoint was time to first treatment adjustment. Secondary endpoints included frequency of and reasons for treatment adjustments. Time to treatment adjustment was analyzed using Kaplan‐Meier methods.

Results

Among 982 patients, 297 treatment adjustments in 240 (24.4%) patients were identified. The mean (median; interquartile range) time to first treatment adjustment (n = 223) was 8.4 (4.0; 2.0–12.0) months (secukinumab: 14.1 [10.0; 4.0–21.0], adalimumab: 11.0 [7.0; 3.0–14.5], ustekinumab: 11.0 [6.0; 2.0–16.0], ixekizumab: 5.8 [3.0; 2.0–8.5], guselkumab: 5.1 [3.0; 2.0–7.0]). The most frequent adjustment type was starting concomitant treatment(s) (10.4% of patients); insufficient skin effectiveness was the most frequent reason for adjustment.

Conclusions

Biological treatment adjustments are frequent in moderate‐to‐severe psoriasis; flexible dosing regimens would support optimal management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisHumansAdultMiddle AgedMaleFemaleRetrospective StudiesGermanyAgedDermatologic AgentsYoung AdultSeverity of Illness IndexAdolescentBiological TherapyTreatment OutcomeAntibodies, Monoclonal, HumanizedBiological Products

Stichwörter der Autor:innen

Inflammationinterleukinpsoriasis

Substanzen

Dermatologic AgentsAntibodies, Monoclonal, HumanizedBiological Products

Autor:innen und Institutionen

  • Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
  • Medical Immunology Department, AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany.
  • e.factum GmbH, Butzbach, Germany.

ORCID-Profile: Matthias Augustin

Zitieren

APA

Kirsten, N., Rubant, S., Gomis-Kleindienst, S., Pfeiffer-Vornkahl, H., & Augustin, M. (2024). Treatment adjustment in biologic therapies for moderate‐to‐severe plaque psoriasis: a German retrospective chart review (TABU). JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15448

Vancouver

Kirsten N, Rubant S, Gomis-Kleindienst S, Pfeiffer-Vornkahl H, Augustin M. Treatment adjustment in biologic therapies for moderate‐to‐severe plaque psoriasis: a German retrospective chart review (TABU). JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2024. doi:10.1111/ddg.15448

BibTeX
@article{Kirsten2024,
  author = {Kirsten, Natalia and Rubant, Simone and Gomis-Kleindienst, Susana and Pfeiffer-Vornkahl, Heike and Augustin, Matthias},
  title = {Treatment adjustment in biologic therapies for moderate‐to‐severe plaque psoriasis: a German retrospective chart review (TABU)},
  journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
  year = {2024},
  doi = {10.1111/ddg.15448}
}
Kostenlos starten →